Sompraz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

**Sompraz HP** is a brand name for a combination product containing **esomeprazole, amoxicillin, and clarithromycin**, used for the eradication of *Helicobacter pylori*. ## Overview Sompraz HP is a triple therapy regimen for *H. pylori* eradication. Esomeprazole is a proton pump inhibitor (PPI), while amoxicillin and clarithromycin are antibiotics. ## Primary Indications * Eradication of *Helicobacter pylori* in patients with peptic ulcer disease or a history of peptic ulcer disease. ## Adult Dosing The typical adult dose is one kit, taken twice daily for 10 days. Each kit contains: * Esomeprazole 20 mg delayed-release capsule * Amoxicillin 500 mg capsule * Clarithromycin 250 mg tablet * **Administration:** Take all components of the kit twice daily, 30 minutes before breakfast and 30 minutes before the evening meal, for 10 consecutive days. ## Pediatric Dosing Dosing for Sompraz HP in pediatric patients is not established. Separate components of the regimen may be dosed based on pediatric guidelines, but this combination product is not indicated for children. ## Dose Adjustments * **Renal Impairment:** No dose adjustment is typically required for esomeprazole, amoxicillin, or clarithromycin in mild to moderate renal impairment. However, caution and potential dose adjustment may be warranted in severe renal impairment for amoxicillin and clarithromycin. * **Hepatic Impairment:** For esomeprazole, reduce the dose of esomeprazole to 20 mg once daily in severe hepatic impairment. Dosing for amoxicillin and clarithromycin generally does not require adjustment in hepatic impairment unless severe. ## Contraindications * Hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any component of the formulation. * History of allergic reactions to penicillins, cephalosporins, or macrolides. * Concomitant use of ergotamine or dihydroergotamine with clarithromycin. * Use in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use. * Severe hepatic impairment. ## Adverse Effects Common adverse effects may include diarrhea, nausea, abdominal pain, taste disturbances, headache, and allergic reactions. More serious adverse effects can include *Clostridioides difficile*-associated diarrhea, liver enzyme elevations, hypersensitivity reactions, and QT prolongation (clarithromycin). ## Key Drug Interactions * **Clarithromycin:** Potent inhibitor of CYP3A4. Interactions with numerous drugs metabolized by CYP3A4 (e.g., statins, certain antifungals, anticoagulants, calcium channel blockers, certain antiretrovirals). Avoid with ergotamine and dihydroergotamine. * **Esomeprazole:** Can alter the absorption of other drugs due to pH changes (e.g., ketoconazole, itraconazole, digoxin). May inhibit CYP2C19 and CYP3A4, potentially affecting metabolism of drugs like clopidogrel. * **Amoxicillin:** May decrease the efficacy of oral contraceptives. ## Monitoring * Monitor for signs of hypersensitivity reactions. * Monitor for diarrhea and signs of *Clostridioides difficile*-associated diarrhea. * Monitor liver function tests, especially with prolonged use or in patients with hepatic impairment. * Confirm *H. pylori* eradication status as per local guidelines, typically 4-8 weeks after treatment completion. ## Clinical Pearls * Ensure patients understand the full 10-day regimen and take all components as directed to maximize eradication rates. * Advise patients to report any severe diarrhea, rash, or signs of allergic reaction immediately. * Consider local resistance patterns for clarithromycin when selecting *H. pylori* eradication therapy. If clarithromycin resistance is high (>20%), alternative regimens may be preferred. * This combination is a fixed-dose product. If dose adjustments are needed for individual components due to renal or hepatic impairment, separate agents will be required. *** *This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines for definitive guidance. Local formularies and prescribing protocols may vary.*